CTR buys preclinical toxic company

Center for Translational Research Sweden AB (CTR) acquires Toxicology Knowledge Team Sweden AB (TKT), which further strengthens the CTR group with optimized toxicological support. Since April 1, TKT has been a wholly owned subsidiary of the holding company CTR.

The activities at TKT continue without interruption, with the same staff and in the same premises in Södertälje, Sweden. Elinor Hahne continues to lead the team as CEO. The company thereby strengthens its partnership with the other companies within the CTR Group, which means shorter communication paths and a simplified connection between pre-clinic and clinic.

"We are very proud to welcome the TKT team to CTR. Their toxicological expertise combined with the CTR companies' expertise in clinical translational research enables us to offer our customers a much more efficient service in bringing new products to market. This benefits patients who can get faster access to new and improved products", says Bengt Dahlström, Chairman of the Board at CTR.

Elinor Hahne, CEO of TKT comments: "We are very pleased to now be part of the CTR group and look forward to adding even more value and expertise to our customers."

With seven PhD toxicologists, TKT is one of the largest toxicology consulting companies in the Nordic region. The company was founded in 2012 and has since then provided expert advice to a large number of customers in the development of pharmaceuticals and medical devices that thereby achieved approval for clinical studies. All consultants have solid experience and knowledge in risk assessment of pharmacologically active substances, inactive ingredients, impurities and leachables from containers and equipment.

CTR was founded in 2016 and is the holding company of a growing group of CRO's engaged in translational research. CTR owns Clinical Trial Consultants AB, RegSmart Life Science AB, Lablytica Life Science AB and ClinSmart Sweden AB.